Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending
Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved for Sanfilippo syndrome Type A.
Stocks · News reference
Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M
https://event.choruscall.com/mediaframe/webcast.html?webcastid=1t78iDYA
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ultragenyx Pharmaceutical shares are trading higher after the company announced the FDA approval of FAYUVI for treatment of pediatric patients with mucopolysaccharidosis type IIIA.
8-K filing — Ultragenyx Pharmaceutical Inc. (RARE)
Filed: 2026-09-17 AccNo: 0001515673-26-000006 Size: 146 KB Item 8.01: Other Events